JP2023528039A5 - - Google Patents

Info

Publication number
JP2023528039A5
JP2023528039A5 JP2022573508A JP2022573508A JP2023528039A5 JP 2023528039 A5 JP2023528039 A5 JP 2023528039A5 JP 2022573508 A JP2022573508 A JP 2022573508A JP 2022573508 A JP2022573508 A JP 2022573508A JP 2023528039 A5 JP2023528039 A5 JP 2023528039A5
Authority
JP
Japan
Prior art keywords
target rna
modified
domain
polynucleotide
polynucleotide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528039A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034301 external-priority patent/WO2021242889A1/en
Publication of JP2023528039A publication Critical patent/JP2023528039A/ja
Publication of JP2023528039A5 publication Critical patent/JP2023528039A5/ja
Pending legal-status Critical Current

Links

JP2022573508A 2020-05-26 2021-05-26 改変環状ポリヌクレオチド Pending JP2023528039A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029996P 2020-05-26 2020-05-26
US63/029,996 2020-05-26
US202063112488P 2020-11-11 2020-11-11
US63/112,488 2020-11-11
US202063119902P 2020-12-01 2020-12-01
US63/119,902 2020-12-01
US202163178056P 2021-04-22 2021-04-22
US63/178,056 2021-04-22
PCT/US2021/034301 WO2021242889A1 (en) 2020-05-26 2021-05-26 Engineered circular polynucleotides

Publications (2)

Publication Number Publication Date
JP2023528039A JP2023528039A (ja) 2023-07-03
JP2023528039A5 true JP2023528039A5 (cg-RX-API-DMAC7.html) 2024-05-09

Family

ID=76523478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573508A Pending JP2023528039A (ja) 2020-05-26 2021-05-26 改変環状ポリヌクレオチド

Country Status (4)

Country Link
US (1) US20230174977A1 (cg-RX-API-DMAC7.html)
EP (1) EP4158017A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023528039A (cg-RX-API-DMAC7.html)
WO (1) WO2021242889A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020313143B2 (en) * 2019-07-12 2024-04-04 Peking University Targeted RNA editing by leveraging endogenous adar using engineered RNAs
CA3159799A1 (en) * 2019-12-02 2021-06-10 Prashant MALI Engineering circular guide rnas
US11827880B2 (en) 2019-12-02 2023-11-28 Shape Therapeutics Inc. Therapeutic editing
WO2022150773A2 (en) * 2021-01-11 2022-07-14 The Regents Of The University Of California Ribozyme-activated rna constructs and uses thereof
JP2024504608A (ja) * 2021-01-12 2024-02-01 北京大学 遺伝子操作rnaを使用した内因性adarの活用による標的化rnaの編集
EP4355902A4 (en) * 2021-06-17 2025-04-30 The Board Of Trustees Of The University Of Illinois Crispr cascade
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
CN118995701A (zh) * 2023-05-17 2024-11-22 中国科学院遗传与发育生物学研究所 基于环状rna的引导编辑系统
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025137637A2 (en) * 2023-12-21 2025-06-26 Shape Therapeutics Inc. Wobble base pairs for improving specificity of rna editing
WO2025207635A1 (en) * 2024-03-25 2025-10-02 University Of Wyoming Compositions and methods for stabilizing a biological material or biologically-derived material
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150299702A1 (en) * 2012-11-30 2015-10-22 Aarhus Universitet Circular rna for inhibition of microrna
AU2015367378A1 (en) * 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3475424A1 (en) * 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018237372A1 (en) * 2017-06-23 2018-12-27 Cornell University RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT
CN119193702A (zh) * 2018-09-06 2024-12-27 加利福尼亚大学董事会 经由改造的adar募集的rna和dna碱基编辑
AU2020313143B2 (en) * 2019-07-12 2024-04-04 Peking University Targeted RNA editing by leveraging endogenous adar using engineered RNAs
CA3159799A1 (en) * 2019-12-02 2021-06-10 Prashant MALI Engineering circular guide rnas

Similar Documents

Publication Publication Date Title
Qiao et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver
CN109072235B (zh) 通过核递送crispr/cas9追踪并操纵细胞rna
JP2023527354A5 (cg-RX-API-DMAC7.html)
EP3129485B1 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
AU2017379073B2 (en) Compositions and methods for treating alpha-1 antitrypsin deficiency
US20060234247A1 (en) Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
Moshiri et al. Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma
JP2021511047A5 (cg-RX-API-DMAC7.html)
CN112930395A (zh) 靶向rna的融合蛋白组合物和使用方法
CN101460624B (zh) 具有iNOS的表达控制作用的正义寡核苷酸以及含有其的组合物
WO2023165009A1 (zh) 一种用于制备环状rna的载体及其应用
JP2022505381A5 (cg-RX-API-DMAC7.html)
JP2005501557A5 (cg-RX-API-DMAC7.html)
IL292999A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
Valdmanis et al. RNA interference–induced hepatotoxicity results from loss of the first synthesized isoform of microRNA-122 in mice
BR112016023004B1 (pt) Sirna, estrutura oligo rna de fita dupla, nanopartícula, composição farmacêutica e estrutura liofilizada para prevenir ou tratar fibrose ou doenças respiratórias contendo a mesma
JP2024504608A (ja) 遺伝子操作rnaを使用した内因性adarの活用による標的化rnaの編集
WO2019196887A1 (zh) 一种新型小激活rna
Mendoza et al. Structural and functional effects of inosine modification in mRNA
JP2024543782A (ja) Cagリピート疾患を治療するための組成物および方法
JP2021511035A5 (cg-RX-API-DMAC7.html)
JP2022534627A (ja) Dmpk遺伝子を標的とした筋ジストロフィーの治療方法
JP2022522166A5 (cg-RX-API-DMAC7.html)
Garcia-Guerra et al. Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs
CN113584027B (zh) 一种激活p21基因表达的方法